Inhibition of the upregulated phosphodiesterase 4D isoforms improves SERCA2a function in diabetic cardiomyopathy

Documenti analoghi

• Inhibition of the calcineurin/forkhead box O1/fatty acid binding protein 4 pathway prevents SERCA2 dysfunction‐induced foam cell formation and atherosclerosis
  di: Beibei Zhu, et al.
  Pubblicazione: (2025)
• Inhibition of GRK2 mitigates cisplatin‐induced acute and chronic nephrotoxicity by targeting the NADPH oxidase 4/oxidative stress axis
  di: Fei Duan, et al.
  Pubblicazione: (2026)
• Identification of new small molecules for selective inhibition of SERCA 1 in patient‐derived metastatic papillary thyroid cancer
  di: Seok‐Mo Kim, et al.
  Pubblicazione: (2025)
• An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors
  di: Kürsat Kirkgöz, et al.
  Pubblicazione: (2025)
• The NADPH oxidase inhibitor Vas2870 prevents myocyte ferroptosis and improves cardiac remodelling and function in doxorubicin‐induced cardiomyopathy
  di: Jing Wang, et al.
  Pubblicazione: (2026)